CORPORATES Suven Life Sciences achieves 100% enrollment for Phase-2b Trial of Ropanicant for major depressive disorder Dec 11, 2025
CORPORATES Suven Life Sciences reports positive Phase-2a results for Ropanicant in treating Major Depressive Disorder Sep 18, 2024